We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased... Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome. Show more
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company...
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported...
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a...
REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, will showcase the...
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a leading life science innovator shaping the future of proteomics, is set to present significant advancements...
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that...
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2101 | 10.4527363184 | 2.01 | 2.4599 | 2 | 431654 | 2.21751949 | CS |
4 | 0.2401 | 12.1262626263 | 1.98 | 2.4599 | 1.82 | 218911 | 2.07314481 | CS |
12 | 0.5701 | 34.5515151515 | 1.65 | 2.4599 | 1.585 | 289100 | 1.84492948 | CS |
26 | 0.2201 | 11.005 | 2 | 2.4599 | 1.56 | 427161 | 1.81476667 | CS |
52 | 0.6401 | 40.5126582278 | 1.58 | 2.4599 | 1.455 | 455485 | 1.80819936 | CS |
156 | -27.1199 | -92.4331970007 | 29.34 | 31.8315 | 1.455 | 396693 | 6.26816914 | CS |
260 | -45.7799 | -95.3747916667 | 48 | 86.55 | 1.455 | 418612 | 16.82388339 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions